Enterprise Value
87.58M
Cash
24.35M
Avg Qtr Burn
-6.62M
Short % of Float
1.98%
Insider Ownership
1.33%
Institutional Own.
1.91%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pelareorep + gemcitabine, nab-paclitaxel, atezolizumab Details Pancreatic cancer, Cancer | Phase 3 Initiation | |
Pelareorep + paclitaxel + avelumab (Bavencio®) Details Breast cancer | Phase 2 Data readout | |
Pelareorep + Retifanlimab Details Breast cancer, Triple-negative breast cancer | Phase 2 Update | |
Pelareorep + Atezolizumab (Tecentriq) Details Gastric cancer, Colorectal cancer , Cancer, Pancreatic cancer | Phase 1/2 Data readout | |
Pelareorep + modified FOLFIRINOX Details Pancreatic cancer | Phase 1/2 Initiation | |
Pelareorep + Keytruda® Details Pancreatic cancer, Sarcoma | Failed Discontinued |